$0Equity raised, all time0 equity rounds sourced so far
—Latest valuationnot disclosed
$46.6MDebt financingnot counted as equity · all in 2025–2026
Rounds over time log-scaled amounts
Funding history 1 round · 1 source
Earlier rounds not yet sourced. Connexin raised before 16 Oct 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
Financing package (facilities)Debt · not equity
Amount$46.6MGBP 35M
Post-money—
◔ Reported
Also
Santander UK, PATRIZIA
Note
Up to GBP 35M package, not a single equity round: GBP 10M Santander UK facility, GBP 5M revolving trade facility (provider not named), GBP 10M financing through PATRIZIA-managed funds, GBP 10M accordion facility (provider not named, uncommitted). Debt-type facilities, so stage debt; equity or debt not stated by the article itself. ISPreview (search result, 15 Oct 2026) reports the same package but returned 429 and was not opened. Note that the GBP 10M PATRIZIA line is named by the article as financing through PATRIZIA-managed funds, not as an equity investment. Microbiotica); approximate. Verified 2026-11-16: BusinessCloud gives 'Hull-headquartered Connexin', the four facilities (GBP 10M Santander UK, GBP 5M revolving trade facility, GBP 10M PATRIZIA-managed funds, GBP 10M accordion) and no equity component stated. The committed Santander and PATRIZIA lines alone are about GBP 20M. USD figure is an approximate conversion at 1.33 USD/GBP (median of source-stated conversions in the dataset for 2026Q4).
Took part only in debt or secondary rounds, so they are not counted as investors and draw no links on the globe.
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Connexin and its logo are trademarks of their owners, used here for identification only.